Vascular Disruptive Agents for the Treatment of Cancer
MEDICAL LITERATURES AND UNIVERSITY PASSWORDS :: Medical E-books Departments :: Oncology & Radiotherapy
Page 1 of 1
Vascular Disruptive Agents for the Treatment of Cancer
Vascular Disruptive Agents for the Treatment of Cancer by Tim Meyer
2010 | ISBN: 1441966080, 1489982264 | PDF
Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).
2010 | ISBN: 1441966080, 1489982264 | PDF
Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).
microbehunter- Moderator
- Posts : 532
Join date : 2016-04-22
Similar topics
» Vascular Dementia: Risk Factors, Diagnosis and Treatment
» Angioplasty, Various Techniques and Challenges in Treatment of Congenital and Acquired Vascular Stenoses
» Disruptive Behavior Disorders
» The Wiley Handbook of Disruptive and Impulse-Control Disorders
» ANTIFUNGAL AGENTS
» Angioplasty, Various Techniques and Challenges in Treatment of Congenital and Acquired Vascular Stenoses
» Disruptive Behavior Disorders
» The Wiley Handbook of Disruptive and Impulse-Control Disorders
» ANTIFUNGAL AGENTS
MEDICAL LITERATURES AND UNIVERSITY PASSWORDS :: Medical E-books Departments :: Oncology & Radiotherapy
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|
19/9/2024, 2:21 pm by pao4ever13
» END NOTE REFERENCING SOFTWARE
19/9/2024, 2:20 pm by pao4ever13
» Handbook of Cancer Treatment-Related Toxicities
18/9/2024, 9:33 pm by aadityaaps
» Orthodontically Driven Corticotomy: Tissue Engineering to Enhance Orthodontic and Multidisciplinary Treatment 2015
16/9/2024, 4:43 pm by mariangeorge
» Orthodontic Treatment of Impacted Teeth, 3rd Ed
16/9/2024, 4:32 pm by mariangeorge
» Osborn's Brain: Imaging, Pathology, and Anatomy 2nd Edition
16/9/2024, 10:15 am by shouldberight
» How to retrieve a University proxy Tutorial Method 1
16/9/2024, 3:15 am by aarturoap
» What is Ezproxy ? How to Use ?
16/9/2024, 3:14 am by aarturoap
» Clinical Success in Invisalign Orthodontic Treatment
15/9/2024, 9:55 pm by mariangeorge
» Mount Sinai Expert Guides Psychiatry
15/9/2024, 9:33 pm by losxmen
» Hypochondriasis and Health Anxiety: A Guide for Clinicians
15/9/2024, 9:27 pm by losxmen
» Diagnosis Made Easier: Principles and Techniques for Mental Health Clinicians (Second Edition)
15/9/2024, 9:22 pm by losxmen
» Radiofrequency Treatments on the Spine
13/9/2024, 11:13 pm by fer88
» collection springer 56 ebboks neurology (2020).epub.eng
13/9/2024, 11:11 pm by fer88
» Drugs in Psychiatry 2nd Edition
13/9/2024, 6:48 pm by Andrew Aung